The Prognostic Significance of Fibrosis Detection in Ischemic and Non-ischemic Cardiomyopathy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cardiomyopathy
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
- Enrollment
- 3000
- Locations
- 1
- Primary Endpoint
- All cause mortality
- Status
- Recruiting
- Last Updated
- 8 years ago
Overview
Brief Summary
The presence of scar within heart muscle can act as a substrate for abnormal rhythm problems and lead to the developement of heart failure
Clinical significance Correlation with biomarkers and genetic markers
Detailed Description
Patients will undergo cardiovascular magnetic resonance (CMR) to include measurement of left ventricular volumes, ejection fraction, detection of inflammation (via STIR sequences) where appropriate, early gadolinium enhancement, late gadolinium enhancement, first pass perfusion using pharmacological stress imaging (contraindications to include comorbidities that do not permit pharmacological stress agents e.g. severe asthma, severe or symptomatic aortic stenosis)
Investigators
Sanjay Prasad
Consultant Cardiologist
Royal Brompton & Harefield NHS Foundation Trust
Eligibility Criteria
Inclusion Criteria
- •presence of an ischaemic or non-ischaemic cardiomyopathic process
- •no contraindication to contrast enhanced CMR
Exclusion Criteria
- •Contraindication to CM R
Outcomes
Primary Outcomes
All cause mortality
Time Frame: 3 years
Ventricular arrhythmias
Time Frame: 3 years
Unplanned heart failure admissions
Time Frame: 3 years
Secondary Outcomes
- Ejection fraction(3)
- NYHA status(3)